Confluence Pharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series B
  • (In Progress)

  • Latest Deal Amount
  • $1.1M

  • Investors
  • 6

Confluence Pharmaceuticals General Information

Description

Developer of therapeutic medications intended to treat rare orphan neurological disorders. The company's medications offer clinically-discovered treatment for core social and communication impairments caused by fragile X syndrome and autism spectrum disorders and benefit similarly anchored disorders like Rett Syndrome and Treatment-Resistant Anxiety, enabling healthcare providers to treat their patients and improve their lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 27628 Will Parker Road
  • Arcadia, IN 46030
  • United States
+1 (317)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • 27628 Will Parker Road
  • Arcadia, IN 46030
  • United States
+1 (317)

Confluence Pharmaceuticals Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Confluence Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series B) 25-Aug-2023 $1.1M In Progress Clinical Trials - General
9. Later Stage VC 10-Feb-2023 Completed Clinical Trials - General
8. Later Stage VC (Series B1) 28-Feb-2022 Completed Clinical Trials - General
7. Later Stage VC (Series B) 13-Sep-2021 Completed Clinical Trials - General
6. Later Stage VC 18-Nov-2020 Completed Clinical Trials - General
5. Debt - General 16-Jul-2020 Completed Clinical Trials - General
4. Later Stage VC (Series B) 24-Feb-2020 Completed Clinical Trials - General
3. Later Stage VC (Series B) 01-Mar-2019 Completed Clinical Trials - General
2. Later Stage VC (Series A2) 07-Nov-2017 $1.6M $4.2M Completed Clinical Trials - General
1. Early Stage VC (Series A1) 01-Nov-2013 $2.6M $2.6M Completed Pre-Clinical Trials
To view Confluence Pharmaceuticals’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Confluence Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic medications intended to treat rare orphan neurological disorders. The company's medications off
Drug Discovery
Arcadia, IN
4 As of 2025

Burlington, MA
 

Rehovot, Israel
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Confluence Pharmaceuticals Competitors (12)

One of Confluence Pharmaceuticals’s 12 competitors is Minerva Neurosciences, a Formerly VC-backed company based in Burlington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Minerva Neurosciences Formerly VC-backed Burlington, MA
NeuroDerm Formerly VC-backed Rehovot, Israel
Marinus Pharmaceuticals Private Equity-Backed Radnor, PA
Vertex Pharmaceuticals Formerly VC-backed Boston, MA
Zynerba Pharmaceuticals Formerly VC-backed Plymouth, PA
You’re viewing 5 of 12 competitors. Get the full list »

Confluence Pharmaceuticals Patents

Confluence Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200163895-A1 Formulations of homotaurines and salts thereof Active 17-May-2017
AU-2021225172-A1 Formulations of homotaurines and salts thereof Active 17-May-2017
AU-2018269557-B2 Formulations of homotaurines and salts thereof Active 17-May-2017
AU-2018269557-A1 Formulations of homotaurines and salts thereof Active 17-May-2017
CA-3062834-A1 Formulations of homotaurines and salts thereof Pending 17-May-2017 A61P25/00
To view Confluence Pharmaceuticals’s complete patent history, request access »

Confluence Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Confluence Pharmaceuticals Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Indiana 21st Century Research and Technology Fund Government Minority
Foundry Partners Asset Manager Minority
Angel (individual) Minority
Foundry Investment Fund Not-For-Profit Venture Capital Minority
IU Ventures Corporate Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Confluence Pharmaceuticals FAQs

  • When was Confluence Pharmaceuticals founded?

    Confluence Pharmaceuticals was founded in 2010.

  • Where is Confluence Pharmaceuticals headquartered?

    Confluence Pharmaceuticals is headquartered in Arcadia, IN.

  • What is the size of Confluence Pharmaceuticals?

    Confluence Pharmaceuticals has 4 total employees.

  • What industry is Confluence Pharmaceuticals in?

    Confluence Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Confluence Pharmaceuticals a private or public company?

    Confluence Pharmaceuticals is a Private company.

  • What is Confluence Pharmaceuticals’s current revenue?

    The current revenue for Confluence Pharmaceuticals is .

  • How much funding has Confluence Pharmaceuticals raised over time?

    Confluence Pharmaceuticals has raised $8.83M.

  • Who are Confluence Pharmaceuticals’s investors?

    Indiana 21st Century Research and Technology Fund, Foundry Partners, , Foundry Investment Fund, and IU Ventures are 5 of 6 investors who have invested in Confluence Pharmaceuticals.

  • Who are Confluence Pharmaceuticals’s competitors?

    Minerva Neurosciences, NeuroDerm, Marinus Pharmaceuticals, Vertex Pharmaceuticals, and Zynerba Pharmaceuticals are some of the 12 competitors of Confluence Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »